|Bid||30.95 x 900|
|Ask||31.97 x 800|
|Day's Range||29.61 - 31.06|
|52 Week Range||13.88 - 33.44|
|Beta (3Y Monthly)||0.63|
|PE Ratio (TTM)||121.34|
|Earnings Date||Feb 12, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.50|
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.
Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.
In the first nine months of 2018, Vanda Pharmaceuticals’ (VNDA) Hetlioz sales grew ~28% YoY to reach $83.4 million from $65.0 million. Fanapt earned revenues of $56.7 million in this period, reflecting ~2% YoY growth. In the third quarter, Hetlioz and Fanapt reported revenues of $29.9 million and $19.2 million, respectively, reflecting ~34% and ~1% YoY growth.
In the first nine months of 2018, Vanda Pharmaceuticals’ (VNDA) net revenues grew ~16% YoY to reach $140.1 million from $120.8 million. In the third quarter, the company’s net revenues amounted to $49.1 million, reflecting ~19% YoY growth. Wall Street analysts estimate that Vanda Pharmaceuticals will generate revenues of $191.7 million in fiscal 2018.
On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.
Biotech stocks Vanda and Innoviva are both near buy points, showing some technical strength, despite the stock market correction.
WASHINGTON , Dec. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's Supplemental ...
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 7% during October and average hedge fund losing about 3%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by about […]
If you're interested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
WASHINGTON , Dec. 10, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that HETLIOZ ® (tasimelteon) improved sleep quality and increased sleep duration in patients ...
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA